ALK-Abello B
CPSE:ALKB
Denmark / Healthcare / Pharmaceuticals
ALK B News
Welcome to Your News Upgrade
Be the First to Know and Act on Market Moving News.
ITULATEK ® approved for treatment of children and adolescents in Canada
ALK (ALKB:DC / OMX: ALK B) today announced that Health Canada has approved ALK’s regulatory filing for ITULATEK ® (tree pollen...
ALK Abello stock up 5% after strong first-quarter earnings
Investing.com -- Shares of ALK Abello climbed 5% following the company’s release of its first-quarter results, which surpassed...
ALK-Abello shares rise following 4Q earnings report
Investing.com -- Shares of ALK-Abello A/S (CPH:ALK-B) climbed 2.5% as the company’s fourth-quarter sales came close to consensus...
ALK-Abello A/S (ALKB:DC) receives Investment Bank Analyst Rating Update
ALK-Abello B receives Investment Bank Analyst Rating Update
ALK-Abello A/S receives Investment Bank Analyst Rating Update
BRIEF-ALK-Abello Announces Health Canada Approval Of Itulatek Slit-Tablets For The Treatment Of Tree Pollen Allergy
April 20 (Reuters) - ALK-Abello A/S ALKb.CO : * REG-ALK ANNOUNCES HEALTH CANADA APPROVAL OF ITULATEK SLIT-TABLETS FOR THE...
BRIEF-ALK-Abello Submits Registration Application For Tree SLIT-Tablet In Canada
June 24 (Reuters) - ALK-Abello A/S ALKb.CO : * REG-ALK SUBMITS REGISTRATION APPLICATION FOR TREE SLIT-TABLET IN CANADA * ALK...
UPDATE 1-In Europe, Mylan's rivals try to plug EpiPen shortages
By Ben Hirschler LONDON, May 10 (Reuters) - European makers of emergency allergy treatments are stepping up production of...
In Europe, Mylan's rivals try to plug EpiPen shortages
LONDON, May 10 (Reuters) - European makers of emergency allergy treatments are stepping up production of alternative life-saving...